spacer
home > ict > autumn 2009 > asean all-stars
PUBLICATIONS
International Clinical Trials

ASEAN All-Stars

 

The clinical trial landscape has changed dramatically over the past decade. Whereas at the turn of the century, almost all clinical trial research was carried out in the US and western Europe, US-based drug sponsors indicate that up to 50 per cent of studies are now conducted outside of the US and expect that figure to increase to 65 per cent within three years (1). In 1990, clinical trials were conducted in about 28 countries worldwide. In September 2009, the FDA was regulating 78,276 trials in 172 countries, and the European Medicines Agency (EMEA) expects the trend to conduct more clinical trials in developing nations to increase in years to come.

There are a number of reasons for this shift. Lower costs, access to large numbers of treatment-naïve patients, the potential for fast patient recruitment and the opportunity to expand their presence in emerging markets are among the top reasons pharmaceutical companies are now conducting trials in developing nations. South-east Asia is an increasingly popular destination because it offers all of these benefits.


Read full article from PDF >>

Rate this article You must be a member of the site to make a vote.  
Average rating:
0
     

There are no comments in regards to this article.

spacer
Gary Muddyman is the Managing Director and CEO of Conversis, a leading provider of globalisation, internationalisation, localisation and translation services, specialising in the life sciences sector. Gary started Conversis back in 2003 with the intention of advancing the understanding and use of localisation and translation as a strategic business tool. Before that, he spent 16 years at HSBC.
spacer
Garry Muddyman
spacer
spacer
Print this page
Send to a friend
Privacy statement
News and Press Releases

Cargolux pledges millions to support Ukraine

Luxembourg, 4 March 2022 – Cargolux will donate a total of EUR 3.5 million to support humanitarian efforts arising from the war in Ukraine. This monetary assistance follows the UN’s emergency appeal for US$1.7 billion to urgently deliver humanitarian support to people in Ukraine and those who have fled the country in search of safety and protection.
More info >>

White Papers

The BioPharmaSpec Approach”: Mass Spectrometry Based Host Cell Protein Identification and Quantitation

BioPharmaSpec

1. Introduction As part of the development of any biopharmaceutical product, the impurities present must be examined, minimized and where possible characterized (1). These impurities fall into two broad categories: product-related impurities (derived specifically from the drug product itself) and process-related impurities (derived from material associated with the production, processing or purification of the sample). Host cell proteins (HCPs) are process-related impurities that require specific analysis due to the multitude of naturally occurring proteins expressed in the production cell line.
More info >>

 

 

 

©2000-2011 Samedan Ltd.
Add to favourites

Print this page

Send to a friend
Privacy statement